Charles Schwab
VRCA icon

Charles Schwab’s Verrica Pharmaceuticals VRCA Stock Holding History

Charles Schwab’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,951
Closed -$44K – 3583
2025
Q1 		$44K Buy
9,951
+5,586
+128% +$36.1K ﹤0.01% 3414
2024
Q4 		$30.6K Sell
4,365
-764
-15% -$8.4K ﹤0.01% 3469
2024
Q3 		$74.4K Hold
5,129
– – ﹤0.01% 3391
2024
Q2 		$374K Sell
5,129
-407
-7% -$31.3K ﹤0.01% 3304
2024
Q1 		$328K Hold
5,536
– – ﹤0.01% 3156
2023
Q4 		$405K Hold
5,536
– – ﹤0.01% 3153
2023
Q3 		$215K Hold
5,536
– – ﹤0.01% 3275
2023
Q2 		$319K Buy
+5,536
New +$336K ﹤0.01% 3212
2023
Q1 		– Sell
-1,257
Closed -$34.6K – 3595
2022
Q4 		$34.6K Hold
1,257
– – ﹤0.01% 3431
2022
Q3 		$37K Buy
+1,257
New +$43.1K ﹤0.01% 3398
2022
Q2 		– Sell
-3,345
Closed -$272K – 3649
2022
Q1 		$272K Hold
3,345
– – ﹤0.01% 3240
2021
Q4 		$307K Hold
3,345
– – ﹤0.01% 3280
2021
Q3 		$419K Buy
3,345
+233
+7% +$26.1K ﹤0.01% 3197
2021
Q2 		$352K Hold
3,112
– – ﹤0.01% 3219
2021
Q1 		$472K Sell
3,112
-51
-2% -$7.06K ﹤0.01% 3098
2020
Q4 		$365K Buy
3,163
+17
+0.5% +$1.56K ﹤0.01% 3094
2020
Q3 		$244K Sell
3,146
-233
-7% -$19.1K ﹤0.01% 3120
2020
Q2 		$372K Hold
3,379
– – ﹤0.01% 2953
2020
Q1 		$370K Buy
3,379
+495
+17% +$65.1K ﹤0.01% 2812
2019
Q4 		$459K Sell
2,884
-507
-15% -$74.8K ﹤0.01% 2850
2019
Q3 		$501K Buy
3,391
+710
+26% +$79.1K ﹤0.01% 2801
2019
Q2 		$312K Buy
2,681
+73
+3% +$6.85K ﹤0.01% 2993
2019
Q1 		$282K Buy
2,608
+1,511
+138% +$174K ﹤0.01% 2956
2018
Q4 		$90K Hold
1,097
– – ﹤0.01% 3099
2018
Q3 		$179K Buy
+1,097
New +$187K ﹤0.01% 3084

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab's VRCA Position: Q2 2025 in Review

Charles Schwab sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 9,951 shares — an estimated $44K sold.

Charles Schwab first reported a position in VRCA in Q3 2018 and held it in 25 quarters. The position peaked at $501K in Q3 2019. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

  • Charles Schwab reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 9,951 Verrica Pharmaceuticals shares in Q2 2025, an estimated $44K.
  • Charles Schwab first reported a position in Verrica Pharmaceuticals in Q3 2018 and held it in 25 quarters.
  • Charles Schwab's Verrica Pharmaceuticals position peaked at $501K in Q3 2019.
  • 58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.